



January 17, 2012

ImmunoCellular Therapeutics to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference

LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, today announced that its President and CEO, Manish Singh Ph.D., will present at the Noble Financial Capital Markets Eighth Annual Equity Conference, being held at the Hard Rock Hotel in Hollywood, Florida from January 16-18, 2012.

ImmunoCellular will present on Tuesday, January 17th, from 2:00 pm to 2:30pm, EST. A webcast of the presentation will be available at the following web address: [Link](#)

Investors and other interested parties who are not attending the conference are invited to listen to the presentation via the webcast. The webcast will be available for 90 days after the presentation.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a randomized, double-blinded, placebo controlled Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma in multiple centers in the United States.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, the risk that IMUC will not be able to secure a licensee for development and commercialization of ICT-107 on favorable terms or at all and the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James Young
Investor Relations
Tel: (212) 732-4300
Email: jyoung@ceocast.com

Source: ImmunoCellular Therapeutics, Ltd.